Arvinas Inc Dossier - Source-backed chat

Arvinas Inc

ARVNNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.48

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $7.74Price as of 30 Sep 2026

Data confidenceNot applicable

Market Cap $499.1M

Enterprise Value $405.3M

Shares Outstanding 63.6M diluted

Moat Rating None

Next Earnings Date4 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Arvinas, Inc. represents a highly compelling, de-risked investment opportunity in the targeted protein degradation (TPD) space. The company achieved a historic milestone with the FDA approval of VEPPANU (vepdegestrant), the first-ever approved PROTAC protein degrader, validating its proprietary platform. By out-licensing VEPPANU to Rigel Pharmaceuticals and maintaining a deep collaboration with Pfizer, Arvinas has shifted commercialization risks to partners while securing substantial milestone and royalty potential. Backed by a robust cash runway extending into the second half of 2028 and a disciplined pipeline prioritization strategy, Arvinas is well-positioned to advance its next-generation oncology and neurology assets, including ARV-102 for neurodegenerative disorders.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets14 analysts · as of 18 Aug 2026

Low · most bearish analyst$6.00

Mean target$14.79

High · most bullish analyst$24.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

The bear case reflects potential clinical or regulatory setbacks, such as disappointing interim data from the VERITAC-2 trial or delays in initiating the ARV-102 Phase 1b trial due to regulatory hurdles. Commercial uptake of VEPPANU by Rigel could be slower than expected, and the company might struggle to find an out-licensing partner for ARV-806 on favorable terms, accelerating cash burn and shortening the operational runway.

Base CaseCentral scenario

The base case assumes steady progress in the commercial transition of VEPPANU via Rigel Pharmaceuticals and Pfizer, with Arvinas receiving its share of the $70.0 million upfront payment and the $15.0 million transition milestone. The company successfully initiates the Phase 1b trial for ARV-102 in PSP in 2H 2026 and secures an out-licensing partner for ARV-806 post-Phase 1. Disciplined R&D and G&A expense management preserves the cash runway into 2H 2028, allowing the stock to re-rate toward historical valuation multiples as clinical milestones are met.

Bull CaseUpside scenario

Arvinas represents a compelling asymmetric risk/reward opportunity. The company is a pioneer in the targeted protein degradation (PROTAC) space, which is projected to grow rapidly. Its lead asset, vepdegestrant, recently received FDA approval (VEPPANU) in May 2026 for ESR1-mutant, ER+/HER2- advanced breast cancer, validating the PROTAC platform and opening up commercialization pathways with partners Pfizer and Rigel. Furthermore, Arvinas has a robust early-to-mid-stage pipeline (including ARV-102 for Parkinson's disease, ARV-393 for B-cell lymphoma, and ARV-806 for KRAS G12D mutations) with multiple clinical readouts scheduled. This pipeline is backed by a strong cash runway of $685.4 million (as of year-end 2025) that is projected to fund operations into the second half of 2028, significantly reducing near-term dilution risk.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Platform Validation: The FDA approval of VEPPANU (vepdegestrant) on May 1, 2026, provides definitive clinical and regulatory validation for Arvinas' PROTAC protein degradation platform.
Strong Financial Position: With $614.9 million in cash, cash equivalents, and marketable securities as of March 31, 2026, the company has a secure runway into the second half of 2028.
Strategic Risk Mitigation: Out-licensing VEPPANU to Rigel Pharmaceuticals and partnering with Pfizer allows Arvinas to capture commercial upside while minimizing direct launch and marketing expenses.
Robust Early-Stage Pipeline: Promising candidates like ARV-102 (LRRK2) for Parkinson's/PSP and ARV-393 (BCL6) for lymphoma offer multiple high-upside clinical catalysts.

Key Investment Risks

Binary Clinical Trial Risk: Near-term valuation is heavily tied to upcoming clinical readouts, particularly the VERITAC-2 Phase 3 trial for vepdegestrant.
Partnership and Execution Dependence: Commercial success and milestone achievements depend heavily on the execution capabilities of partners Pfizer and Rigel Pharmaceuticals.
Out-Licensing Uncertainty: The strategic decision to out-license ARV-806 (KRAS G12D) after Phase 1 introduces the risk of failing to secure a partner or accepting sub-optimal deal terms.
High Cash Burn: As a clinical-stage biotech, Arvinas continues to generate operational losses, making long-term financial sustainability dependent on milestone achievements or future capital raises.

Thesis Invalidation Triggers

Failure of the VERITAC-2 Phase 3 trial to meet its primary efficacy endpoints.
Inability to secure an out-licensing partner for ARV-806 (KRAS G12D) within 12 months of completing the Phase 1 trial.
Severe regulatory delays or clinical holds placed on the ARV-102 neurodegenerative program.
Significant acceleration in cash burn that reduces the cash runway to less than 18 months.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.